Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
m-ceNK cells
i
Other names:
m-ceNK cells, memory cytokine-enriched natural killer cells
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
ImmunityBio
Drug class:
NK cell stimulant, IFNγ stimulant
Related drugs:
‹
pomalidomide (16)
CYNK-101 (8)
SNK01 (4)
IDP-023 (2)
CYNK-001 (2)
AFM13/AB-101 (1)
CTX-8573 (1)
EDIT-202 (1)
FT516 (1)
GDA-501 (1)
GTB-5550 (1)
IPH6501 (1)
KappaMab (1)
SAR443579 (1)
ASP7517 (0)
AgenT-797 (0)
cytotoxic lymphocyte-based cancer vaccine (0)
GCC4001 (0)
CAR-ITNK cells (0)
CAR-NK-CD19 cells (0)
CAR.70/IL15-transduced CB-NK cells (0)
CAR19-CYNK (0)
CB CAR-NK019 (0)
CBT101 (0)
CD123 targeted CAR-NK (0)
CD33/CLL1 dual CAR-NK cell (0)
CDH17 CAR-NK cell therapy (0)
CHM 2301 (0)
CIML NK (0)
CLDN6-CAR-NK cell therapy (0)
CNDO-109 (0)
CNK-UT (0)
CNTY-101 (0)
CT101a (0)
CYTO NK-102 (0)
DC vaccine for prostate cancer (0)
DF8100 (0)
DF9001 (0)
DM919 (0)
FATE-NK100 (0)
FT500 (0)
FT522 (0)
FT555 (0)
GAIA-102 (0)
GDA-201 (0)
GIC-102 (0)
GTA102 (0)
GTB-3650 (0)
GX-051 (0)
IBR733 (0)
primed NK cell therapy (0)
JD001 (0)
JD010 (0)
JD023 (0)
K-NK002 (0)
KN5501 (0)
MG4101 (0)
Magicell-NK (0)
NK/γδ T cell-enriched cell therapy (0)
NK92-CD16-158V (0)
NKG2D CAR-NK cell therapy (0)
NKG2D-CAR-NK92 cells (0)
CST-101 (0)
PB103 (0)
PNK-007 (0)
QN-019a (0)
QN-023a (0)
SAR445419 (0)
SAR445514 (0)
SENTI-202 (0)
SMT-NK (0)
SNC103 (0)
SZ003 (0)
SZ011 (0)
Super NK cell therapy (0)
TROP2-CAR-NK (0)
UD TGFbetai NK cells (0)
VAX-NK/HCC (0)
WU-NK-101 (0)
ZM008 (0)
cam1615SS1 (0)
dualCAR-NK19/70 (0)
EC-18 (0)
inaleucel (0)
ALT-801 (0)
interferon gamma-1 b (0)
leukocyte interleukin injection (0)
STAR-LLD SC (0)
pomalidomide (16)
CYNK-101 (8)
SNK01 (4)
IDP-023 (2)
CYNK-001 (2)
AFM13/AB-101 (1)
CTX-8573 (1)
EDIT-202 (1)
FT516 (1)
GDA-501 (1)
GTB-5550 (1)
IPH6501 (1)
KappaMab (1)
SAR443579 (1)
ASP7517 (0)
AgenT-797 (0)
cytotoxic lymphocyte-based cancer vaccine (0)
GCC4001 (0)
CAR-ITNK cells (0)
CAR-NK-CD19 cells (0)
CAR.70/IL15-transduced CB-NK cells (0)
CAR19-CYNK (0)
CB CAR-NK019 (0)
CBT101 (0)
CD123 targeted CAR-NK (0)
CD33/CLL1 dual CAR-NK cell (0)
CDH17 CAR-NK cell therapy (0)
CHM 2301 (0)
CIML NK (0)
CLDN6-CAR-NK cell therapy (0)
CNDO-109 (0)
CNK-UT (0)
CNTY-101 (0)
CT101a (0)
CYTO NK-102 (0)
DC vaccine for prostate cancer (0)
DF8100 (0)
DF9001 (0)
DM919 (0)
FATE-NK100 (0)
FT500 (0)
FT522 (0)
FT555 (0)
GAIA-102 (0)
GDA-201 (0)
GIC-102 (0)
GTA102 (0)
GTB-3650 (0)
GX-051 (0)
IBR733 (0)
primed NK cell therapy (0)
JD001 (0)
JD010 (0)
JD023 (0)
K-NK002 (0)
KN5501 (0)
MG4101 (0)
Magicell-NK (0)
NK/γδ T cell-enriched cell therapy (0)
NK92-CD16-158V (0)
NKG2D CAR-NK cell therapy (0)
NKG2D-CAR-NK92 cells (0)
CST-101 (0)
PB103 (0)
PNK-007 (0)
QN-019a (0)
QN-023a (0)
SAR445419 (0)
SAR445514 (0)
SENTI-202 (0)
SMT-NK (0)
SNC103 (0)
SZ003 (0)
SZ011 (0)
Super NK cell therapy (0)
TROP2-CAR-NK (0)
UD TGFbetai NK cells (0)
VAX-NK/HCC (0)
WU-NK-101 (0)
ZM008 (0)
cam1615SS1 (0)
dualCAR-NK19/70 (0)
EC-18 (0)
inaleucel (0)
ALT-801 (0)
interferon gamma-1 b (0)
leukocyte interleukin injection (0)
STAR-LLD SC (0)
›
Associations
News
Trials
Filter by
Latest
1m
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=50, Recruiting, ImmunityBio, Inc. | Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Jun 2024 --> Mar 2025
1 month ago
Trial completion date • Trial primary completion date • Metastases
|
CD4 (CD4 Molecule) • NKG2D (killer cell lectin like receptor K1)
|
Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
over1year
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=50, Recruiting, ImmunityBio, Inc. | N=30 --> 50 | Trial completion date: Jun 2022 --> Dec 2024 | Trial primary completion date: Jun 2022 --> Jun 2024
over 1 year ago
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
|
Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
over3years
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=30, Recruiting, ImmunityBio, Inc. | Not yet recruiting --> Recruiting
over 3 years ago
Clinical • Enrollment open
|
CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
|
Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
over3years
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=30, Not yet recruiting, ImmunityBio, Inc.
over 3 years ago
Clinical • New P1 trial
|
CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
|
Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login